Tquila Automation raises $20M in Series A funding, acquires healthcare intelligent automation leader Element Blue
Tquila Automation, a startup that offers intelligent automation solutions for the healthcare sector, has closed $20 million in Series A funding. Leading this round is Delta-v Capital, with participation from Tquila and Momentum Partners.
In conjunction with this funding milestone, Tquila Automation has also revealed its acquisition of Element Blue, a prominent provider of intelligent automation solutions. This strategic acquisition is poised to significantly bolster Tquila Automation’s product portfolio, expanding its reach to a broader spectrum of clientele.
Tquila Automation’s suite of products is strategically designed to empower organizations across many sectors with the automation of their operational workflows, fostering efficiency enhancements while concurrently reducing operational costs. These innovative solutions have found resonance across a diverse array of businesses.
On the other hand, Element Blue specializes in automating clinical and administrative workflows for healthcare organizations, a mission shared by Tquila Automation. With the acquisition of Element Blue, the company is poised for an accelerated expansion of its product offerings, aiming to cater to an even wider customer base.
The infusion of capital from the Series A funding round will be instrumental in propelling Tquila Automation’s growth and furthering its product development efforts. As the startup continues to evolve, it remains committed to revolutionizing automation within the healthcare sector, ultimately benefitting healthcare organizations of all scales and specialties.
Founded in 2019 by co-founder and CEO Tom Abbott, the Austin, Texas-based startup Tquila Automation helps businesses of all sizes harness the power of automation to improve efficiency, reduce costs, and boost productivity. The startup is known for its expertise in a wide range of areas, including robotic process automation (RPA), intelligent automation (IA), advisory services, and artificial intelligence (AI).
Commenting on the acquisition, Abbott says, “The acquisition of Element Blue realizes our strategy of building industry specialist capability across the US and Europe. Every sector has very specific needs when it comes to intelligent automation, and healthcare is no exception. It brings together two UiPath specialists to deliver enhanced value and a broader range of capabilities for clients. We’re stronger as one.”
Steven Gerhardt, Element Blue Managing Partner & CEO, adds, “Our future as a combined team is an exciting new chapter. We have a shared vision to be leaders in the intelligent automation market. Element Blue’s 20 years of healthcare leadership, including five years with UiPath, helps position us for long-term success and allows us to offer even greater levels of service and innovation to clients.”